ACME Laboratories's Total Liabilities for the quarter that ended in Mar. 2026 was BDT31,546 Mil.
ACME Laboratories's quarterly Total Liabilities
increased
from Sep. 2025 (BDT31,631.82 Mil) to Dec. 2025 (BDT32,825.39 Mil) but then
declined
from Dec. 2025 (BDT32,825.39 Mil) to Mar. 2026 (BDT31,545.75 Mil).
ACME Laboratories's annual Total Liabilities
increased
from Jun. 2022 (BDT21,284.77 Mil) to Jun. 2023 (BDT27,114.91 Mil) and
increased
from Jun. 2023 (BDT27,114.91 Mil) to Jun. 2024 (BDT30,570.33 Mil).
ACME Laboratories Total Liabilities Related Terms
ACME Laboratories Total Liabilities Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
ACME Laboratories's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of BDT31,546 Mil mean?
ACME Laboratories (DHA:ACMELAB) has a Total Liabilities of BDT31,546 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ACME Laboratories and its competitors.
Is ACME Laboratories' Total Liabilities too high?
ACME Laboratories' current Total Liabilities is BDT31,546 Mil. Overall, ACME Laboratories has a GF Score™ of 90/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Total Liabilities compare to ZTS and UTHR?
ACME Laboratories' Total Liabilities of BDT31,546 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ACME Laboratories and its competitors. ACME Laboratories's current Total Liabilities is BDT31,546 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT125.40, compared to a current price of BDT84.50 — trading 32.6% below its estimated fair value. The current Total Liabilities is BDT31,546 Mil. ACME Laboratories' overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Total Liabilities is BDT31,546 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT84.50 is trading 32.6% below its estimated GF Value™ of BDT125.40.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Total Liabilities: BDT31,546 Mil
GF Value™: BDT125.40 vs. price of BDT84.50 (32.6% below fair value)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
90GF Score
Get the complete analysis for DHA:ACMELAB
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
